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1. Introduction 
 
Patients with chronic kidney disease (CKD) generally die of cardiovascular disease 
(CVD), before even requiring renal replacement therapy. Although we know that any degree 
of decreased renal function or any proteinuria increases cardiovascular (CV) risk the 
mechanism linking CKD and CVD are not fully explained. Beyond tradicional risk factors 
like hypertension, diabetes, obesity and lipid abnormality nontradicional risk factors are 
referred as subclinical target organ damage as well like arterial stiffness, dysfunction of the 
vegetative nervous system, microalbuminuria, or chronic kidney disease.    
 
1.1 Arterial stiffness 
The arterial system has two interrelated haemodynamic function: to deliver an 
adequate blood supply from the heart to the peripheral tissues (the conduit function) and to 
dampen blood flow and pressure oscillation caused by the intermittent character of the left 
ventricle (LV) ejection ensuring peripheral organ perfusion at steady flow (the dampen 
function). About 50 % of stroke volume would be stored during systole in the aorta and large 
elastic arteries stretching the arterial walls. During diastole the accumulated energy recoils the 
aorta squeezing the stored blood forward ensuring a continuous flow. The ability of arteries to 
accommodate the volume ejected by the LV instantaneously can be described as arterial 
compliance or stiffness. Every heart cycle raises a pressure wave transmission along the 
arterial system. In the case of increasing arterial rigidity this pressure wave travels more 
quickly. This traveling can be characterized by the pulse wave velocity (PWV).       
We focused our attention on damaged vascular function as one of the nontradicional 
mechanisms responsible for disproportionate CVD burden in CKD patients. Longitudinal 
epidemiologic studies have demonstrated the independent predictive value of arterial stiffness 
on cardiovascular outcome in hypertension, diabetes and in patients with with end-stage renal 
disease. However, the relationship between arterial stiffness and kidney function in nonuremic 
patients with homogenous chronic renal diseases is unclear.   
 
1.2. The autonomic nervous system 
Autonomic nervous system (ANS) regulates multiple physiological processes 
including heart rate, blood pressure and CV responses to physical or mental stress.  
Autonomic imbalance with increased sympathetic activity and decreased parasympathetic 
tone, have been shown to be a risk factor for CV morbidity and mortality. Recently has been 
published data about the increased sympathetic activity in end-stage renal disease. It has been 
described many non-invasive measures which represent the function of the ANS like resting 
heart rate, hart rate variability, baroreflex sensitivity or heart rate recovery (HRR). During 
graded exercise test the heart rate increases as a result of withdrawal of the parasympathetic 
tone and increased sympathetic activity. After the peak during recovery the heart rate 
decreases depending to the reactivation of the parasympathetic tone and the decrease of the 
sympathetic activity. Earlier studies have evaluated the prognostic significance of HRR in 
patients with different cardiac diseases. Attenuated HRR has been described as a predictor of 
total mortality and sudden cardiac death in coronary artery disease, heart failure, left 
ventricular dysfunction, and after coronary artery revascularization. Cardiovascular risk is 
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increased with any decrease in kidney function. However, any relationship between HRR and 
renal function is unexplored.      
 
1.3. The investigated types of kidney diseases 
 
1.3.1. IgA nephropathy 
IgA nephropathy (IgAN) is the most common, nondiabetic immunologically mediated 
glomerular renal disease in the world. The disease generally progresses slowly over 20 years and thus 
is very suitable for longitudinal cardiovascular risk assessment of blood pressure, lipid value, smoking 
and proteinuria severity.  
 
1.3.2. Polycystic kidney disease 
Polycystic kidney disease (PKD) is the most common inherited renal disease and occurs in 1 
of 400-1000 individuals. In most of cases it shows an autosomal dominant inheritance and two genes 
(polycystin gene 1 and 2) are implicated in its development. The clinical picture is characterized by 
cystic involvement of the kidneys with slow progression to ESRD and by some extrarenal 
cardiovascular manifestations e.g. intra- et extracranial aneurysms, and cardiac valvular defect. It is 
accepted that cardiovascular complications are the main cause of death also in PKD.  
 
2. Aims of the studies 
 
 To assess the arterial stiffness in a type of homogenous chronic renal disease, in 
IgAN, and determine the possible confounding factors influencing the arterial 
stiffening. 
 To investigate the arterial stiffness and compare it in two ethiologically different 
homogenous chronic renal disease, in IgAN and PKD.  
 To asses the HRR in IgAN and analyse its connection with the kidney function and 
other CV risk factors.  
 
 
3. Clinical investigations 
 
3.1. Arterial stiffness in chronic kidney disease 
 
3.1.1. Arterial stiffness in IgA nephropathy. The role of the metabolic parameters 
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We investigated 107 IgAN patients (68 male, 37 female, 45±11 years of age). The 
tradicional CV risk factors (age, gender, hypertension, diabetes, obesity, lipid abnormality, 
smoking habit, and the complete metabolic syndrome-MetS) were analyzed. We performed 24 
hour-ambulatory blood pressure monitoring (ABPM) at every patient. An estimated 
glomerular filtration rate (eGFR) was given calculated by the Cockroft-Gault method. The 
control group contained 35 patients they were free from any renal disease. The renal patients 
were divided into three groups according there kidney function. Group 1 (eGFR ≥ 90 ml/min - 
CKD1 stage, n=45); Group 2 (eGFR 60-89 ml/min, CKD 2 stage, n=37); and Group 3 (eGFR 
15-59 ml/min, CKD 3-4 stage, n=23).  
Several methods are available for the determination of pulse wave velocity (PWV), 
including carotid-femoral or brachial-ankle PWV, applanation tonometry, and echo tracking.  
All reflect the stiffness of the great arteries A simple and validated method for the estimation 
of PWV is finger photoplethysmography. The method enables determining the stiffness index 
(SI), which can be derived from the digital volume pulse (DVP) and is reflected as SIDVP. We 
used the Pulse Trace system (Micro Medical Ltd. Rochester, UK) for the estimation of arterial 
stiffness. A finger clip containing an infrared-light emitting diode and a receiver was applied 
to the index finger of the dominant hand. DVP comprises two distinct waves within one 
cardiac cycle, an early systolic peak arising from pressure wave propagating from the heart 
along the arterial tree to the finger followed by a delayed second peak caused by pressure 
wave reflected backward mainly from the aortic bifurcation. The time between the first peak 
and the inflection point in the waveforms was determined (ΔTDVP). SIDVP was calculated by 
the following equation: SI(m/s) = body height/ΔTDVP . A single waveform was obtained by 
averaging DVP contours during a period of 30 sec. To enhance the accuracy of the 
investigation of SIDVP five period samples were taken and the upper and lower merit of DVP 
was deleted. The remaining three merits were averaged and used in further analysis.  
 
3.1.1.1. Results 
SIDVP of the CKD 3-4 and CKD 2 patients was significantly higher, than SIDVP of the 
control group (11.11 m/s vs. 8.71 m/s; p < 0.001), and (10.36 m/s vs. 8.71; p = 0.013, 
respectively). We did not find any difference in SIDVP between control group and CKD 1 
group (8.71 m/s vs. 9.27 m/s, p = NS, Fig. 1). It was found a significant negative correlation 
between eGFR and SIDVP : r = -0,304; p = 0,002; Fig. 2).  
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 Fig. 1. SIDVP  across the different groups 
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 Fig 2. Correlation between SIDVP and eGFR 
 
Twenty nine from the investigated 105 IgAN patients had MetS. Theirs SIDVP was 
slightly higher, than the patients without MetS, but the difference was not significant (10.65 
m/s vs. 9.83 m/s, p = NS). Patients having at least two or more metabolic risk factors had 
higher SIDVP than patients with one or zero risk factor (10.43 m/s, vs. 9.12 m/s; p = 0.006). 
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Univariate and multivariate analysis was performed to investigate the influence of 11 
confounding factor on arterial stiffness. In univariate model age, hypertension, eGFR and 
dyslipidemia was in connection with SIDVP, while in multivariate analysis only age and 
hypertension had an independent effect on SIDVP. 
Patients with uncontrolled blood pressure (on ABPM more than 130/80 mm Hg) had 
significantly higher SIDVP than patients with well controlled blood pressure (on ABPM ≤ 
130/80 mm Hg), or patients without hypertension (Fig. 3). 
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Fig 3. SIDVP depending on blood pressure control 
 
3.1.2. Different effect on arterial stiffness of IgA nephrpathy and polycystic 
kidney disease  
  
In a cross-sectional study 120 CKD (60 with IgAN and 60 with PKD) and 50 control 
patients were investigated. Their arterial stiffness was compared. To asses the arterial stiffness 
we used the photoplethysmographic method, and the SIDVP was determined. The method of the 
measuring is detailed above. 
 
3.1.2.1. Results 
 
Arterial SI values were as follows: Controls: 8.87 m/s, IgAN group: 9.66 m/s, PKD group: 
11.14 m/s. The SIDVP of PKD group was significantly higher than SIDVP of IgAN patients and 
controls (p<0.001 in both relation) while there was no significant difference in SIDVP values 
between IgAN group and controls (Fig. 4). 
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Fig. 4. SIDVP in the CKD and control groups 
 
The two groups of renal patients were matched according to their eGFR. There were 
24 patients in CKD 3-4 (eGFR 15-59 ml/min) and 36 patients in CKD 1-2 stage (eGFR ≥ 60 
ml/min), in both IgAN and PKD groups. We found that SIDVP of CKD 3-4 IgAN patients was 
significantly higher, than controls (10.43 m/s vs. 8.87 m/s, p<0.05) while SIDVP of CKD 1-2 
IgAN patients (9.15± m/s) did not differed significantly from controls (Fig. 5). 
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 Fig. 5. SIDVP in the IgAN subgroups 
 There was a not significant increase in the stiffening of the CKD 3-4 patients 
compared to the CKD 1-2 IgAN patients. In PKD patients the SIDVP in both groups (CKD3-4 
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and of CKD1-2 patients) was significantly higher, than in controls (11.41 m/s and 10.95 m/s 
vs. 8.87 m/s, p<0.001, respectively, (Fig. 6).  
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Fig. 6. SIDVP in the PKD subgroups 
 
 
There was an inverse significant correlation between SIDVP and GFR in the whole 
CKD group, (IgA+PKD) and in IgAN patients (r = -0.288, p = 0.001 and r=0.368, p<0.01, 
respectively, but in PKD patients there was not (Fig. 7 a-c).  
 
r = -0.288, p =  0.001 
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Fig. 7. The correlation between SIDVP and eGFR in the different groups: a. all CKD 
patients; b. IgAN patients; c. PKD patients 
 
Univariate linear regression analyses were performed in both renal groups to assess the 
confounding factors affecting SIDVP: age, gender, 24-hour systolic, diastolic blood pressure 
and theirs diurnal indeces, mean arterial pressure, pulse pressure, CH metabolic disorder 
(diabetes, IGT or IFG), hypertension in history, dyslipidemia, BMI, hyperuricaemia, eGFR. 
We found that age, diastolic diurnal index and eGFR have significant impact on SIDVP in 
IgANP, while age, eGFR and hypertension were significantly related to SIDVP in PKD. 
However, in a multivariate model only age associated independently with SIDVP in both renal 
groups. 
It is well known that arterial stiffness increases with age. Using an estimated 
regression model to compare the increase of SIDVP during aging in the three groups (PKD, 
IgAN and controls) we found that SIDVP of both PKD and IgAN patients increased 
significantly faster with age, than SIDVP of controls (PKD vs. controls: 0.091-0.073>0, beta: 
0.814, 95% CI: 1.682-3.028, p<0.001; IgAN vs. controls: 0.089-0.073>0, beta: 0.313, 95% 
CI: 1.059-1.764, p<0.05, respectively) (Fig. 8). 
 
 
 
r = -0.229, p = NS 
r = -0.368, p < 0.001 
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Fig. 8. Changing of the SIDVP depending on the age, across the IgAN, PKD and 
control group.   
 
3.1.3. Summary 
 
We identified an increased vascular stiffness in IgAN patients, compared to controls. 
The metabolic syndrome and the presence of metabolic factors may cause a harmful effect on 
arterial stiffness. We confirmed first that chronic kidney diseases of different origin may have 
a distinct influence on SIDVP. In PKD the arterial stiffness is often increased even before the 
worsening of the glomerular function. However, the progression of the arterial stiffening is 
more pronounced in CKD patient, than in controls without any renal disease. 
 
3.2. The importance of the heart rate recovery in IgA nephropathy 
 
3.2.1. Patients and Methods 
 
We studied 107 IgAN patients, who did not have known heart failure, although treated 
coronary artery disease (CAD) was accepted. Left bundle branch block on ECG was an 
exclusion criterion. Patients with manifest symptoms of heart failure (NYHA III-IV) were 
also excluded, as well as patients with atrial fibrillation or severe hypertension (≥180/110 mm 
Hg). All patients that we included were able to perform exercise testing. The cohort included 
71 men and 36 women aged 45±11 years. Written informed consent was obtained in all 
participants after the University ethical committee had approved the study. As is routine in 
our department, the patients had been counseled in a low-sodium diet (100 mmol/day), protein 
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reduction to 0.6-0.8 g/kg/day, they had been advised not to smoke and to exercise regularly. ). 
The tradicional CV risk factors (age, gender, hypertension, diabetes, obesity, lipid 
abnormality, smoking habit), and the actual medical therapy were analyzed.  
To asses the left ventricular systolic condition we performed echocardiography at 
every patient before the stress test. Left ventricular systolic function was characterized by 
ejection fraction (LVEF). The patients underwent a symptom-limited graded exercise 
treadmill test according to the standard Bruce protocol with a goal of achieving the maximum 
predicted heart rate (220 minus age). Beta-blockers and nitrates were stopped at least for 48 
hours before the examination. Continuous 12-lead ECG monitoring was performed 
throughout testing. ECG samples were recorded and printed every minute during the 
examination including the whole recovery. Exercise capacity was expressed in seconds and 
was measured from the zero second of the first step to the termination moment at peak 
exercise. The termination was followed by at least one-minute cool-down period with a 
treadmill speed of 1.6 km per hour. The value for HRR was defined as the difference between 
the heart rate from peak exercise to 1 min after the peak. Analyses were performed off-line on 
printed formats. Diagnosis of CAD was established if horizontal or down-sloping ST 
depression of ≥ 1 mm was found for at least 1 minute in two or more coherent leads.  
Twenty nine patients with normal renal function and without any renal disease formed 
the control group. The indication of cardiac stress test at all patients was to assess the exercise 
capacity and the suspected diagnosis of CAD.   
 
3.2.2. Results 
 
HRR reduction showed significant correlation with decreased eGFR (r=0.422 
p<0.001; Fig 9).  
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Fig. 9. Correlation between HRR and eGFR. 
 
HRR values in CKD 3-4 group (16.3 bpm) were significantly lower compared 
to the patients of CKD 2 group (24.5 bpm, p=0.015), or the CKD 1 group (27.8 bpm, 
p0.001) and the control group (29.9 bpm, p0.001), respectively (Fig 10). There was 
no difference in HRR between the control group, the CKD 1 and CKD 2 groups. HRR 
reduction 
0
5
10
15
20
25
30
35
40
45
HRR 
(beat/minute)
29.9
27.8
24.5
16.3
p =0.015
p < 0.001
P=NS P=NS
Control
IgAN patients
CKD1 CKD2 CKD3-4
 
 Fig. 10. Heart rate recovery in the different groups 
 
Univariate linear regression analysis was performed in renal patients including 23 
confounding variables: gender, age, exercise capacity, CAD, metabolic syndrome, 
hypertension in history, systolic and diastolic BP, systolic and diastolic diurnal index on 
ABPM, pulse pressure, heart rate, BMI, dyslipidemia, carbohydrate metabolic disorder, 
LVEF, smoking habit, hemoglobin level, eGFR, and medical treatment (ACEi/ARB, Ca-
antagonists, beta-blockers and statins) . We found that factors associated with HRR were age, 
systolic 24 hour BP, pulse pressure, systolic diurnal index on ABPM, BMI, dyslipidemia, CH 
metabolic disorder (IFG, IGT or DM), metabolic syndrome, eGFR, ACEI/ARB and statin 
therapy. Only eGFR was independently associated with decreased HRR by multivariate linear 
regression analysis. 
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3.2.3. Summary 
 
Our data suggest that IgA nephropathy patients with decreased renal function (CKD 3-
4) have autonomic imbalance. Furthermore, the effect of kidney damage on increased 
sympathetic activity seems to be more important than other classic cardiovascular risk factors. 
We considered many factors that may have influence on the cardiovascular status of IgA 
nephropathy patients. Our finding suggests the more important role of decreased GFR in the 
development of sympathetic hyperactivity in IgA nephropathy patients than diabetes or other 
established CV risk factors. 
 
 
